Sanofi: drug approved for sleeping sickness in DRC
(CercleFinance.com) - Sanofi has said that the Democratic Republic of Congo (DRC) has granted marketing authorisation to fexinidazole for the treatment of human African trypanosomiasis (HAT), more commonly known as sleeping sickness, caused by the parasite Trypanosoma brucei gambiense.
Transmitted by the bite of a tsetse fly, it causes neuropsychiatric symptoms and is usually fatal in the absence of treatment. About 65 million people are at risk of this disease in sub-Saharan Africa.
On 16 November 2018, The European Medicines Agency (EMA) adopted a positive scientific opinion of fexinidazole, based on the results of clinical trials conducted by the Drugs for Neglected Diseases Initiative (DNDi).
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Transmitted by the bite of a tsetse fly, it causes neuropsychiatric symptoms and is usually fatal in the absence of treatment. About 65 million people are at risk of this disease in sub-Saharan Africa.
On 16 November 2018, The European Medicines Agency (EMA) adopted a positive scientific opinion of fexinidazole, based on the results of clinical trials conducted by the Drugs for Neglected Diseases Initiative (DNDi).
Copyright (c) 2019 CercleFinance.com. All rights reserved.